Phase III FURI study of ibrexafungerp shows positive clinical results in multiple fungal infections – Scynexis

Scynexis announced an oral presentation of analyses of interim data from its ongoing Phase III FURI study showing favorable clinical activity of oral Brexafemme (ibrexafungerp) in severe hospital-based fungal infections across multiple serious fungal infections. Data from an interim analysis of the combined data of 74 patients from the Phase III FURI clinical study evaluating oral ibrexafungerp for the treatment […]

Scynexis announces FDA approval of Brexafemme as the first and only oral non-azole treatment for vaginal yeast infections

Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351 is brought to you by International Medical Information. For more details, visit Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot […]